Compare BON & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | AKTX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 14.4M |
| IPO Year | 2021 | N/A |
| Metric | BON | AKTX |
|---|---|---|
| Price | $1.70 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 40.8K | ★ 1.9M |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $21,610,848.00 | N/A |
| Revenue This Year | $223.38 | N/A |
| Revenue Next Year | $18.82 | N/A |
| P/E Ratio | $0.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $0.22 |
| 52 Week High | $73.75 | $1.73 |
| Indicator | BON | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 37.29 |
| Support Level | $1.45 | $0.27 |
| Resistance Level | $1.73 | $0.31 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 67.64 | 66.36 |
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.